Cartesian Therapeutics Announces Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis Treatment

1. Positive Phase 2b Results: Cartesian Therapeutics announced positive topline results from a Phase 2b trial of Descartes-08 in patients with myasthenia gravis, meeting the primary endpoint with statistical significance.
2. Descartes-08 Efficacy: 71% of patients treated with Descartes-08 showed a clinically meaningful improvement in MG Composite (MGC) score at Month 3 compared to 25% for placebo.
3. Durable Responses: Deep and durable responses were observed in patients treated with Descartes-08 for at least six months.
4. Safety Profile: The safety profile continues to support outpatient administration of Descartes-08 without preconditioning chemotherapy.
5. Endpoint Change: The primary endpoint was changed from the MG-ADL symptom scale to MGC in May, and the analysis was restricted to patients enrolled at academic medical centers.
6. Future Plans: Cartesian Therapeutics plans to hold an End-of-Phase 2 meeting with the FDA by year-end and will host a conference call to discuss the results.